Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Italian Journal of Pediatrics
Published in: Italian Journal of Pediatrics 1/2022

Open Access 01-12-2022 | Pediatric Dermatology | Review

Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP)

Authors: Elena Galli, Anna Belloni Fortina, Giampaolo Ricci, Nunzia Maiello, Iria Neri, Ermanno Baldo, Irene Berti, Domenico Bonamonte, Lucetta Capra, Elena Carboni, Rossella Carello, Francesca Caroppo, Giovanni Cavagni, Iolanda Chinellato, Francesca Cipriani, Pasquale Comberiati, Andrea Diociaiuti, Vito Di Lernia, Marzia Duse, Cesare Filippeschi, Arianna Giannetti, Mattia Giovannini, Amelia Licari, Gian Luigi Marseglia, Manuela Pace, Annalisa Patrizi, Giovanni Battista Pajno, Diego Peroni, Alberto Villani, Lawrence Eichenfield

Published in: Italian Journal of Pediatrics | Issue 1/2022

Login to get access

Abstract

Currently, there are a few detailed guidelines on the overall management of children and adolescents with moderate-severe atopic dermatitis. AD ​​is a complex disease presenting with different clinical phenotypes, which require an individualized and multidisciplinary approach. Therefore, appropriate interaction between primary care pediatricians, pediatric allergists, and pediatric dermatologists is crucial to finding the best management strategy. In this manuscript, members of the Italian Society of Pediatric Allergology and Immunology (SIAIP), the Italian Society of Pediatric Dermatology (SIDerP), and the Italian Society of Pediatrics (SIP) with expertise in the management of moderate-severe atopic dermatitis have reviewed the latest scientific evidence in the field. This narrative review aims to define a pathway to appropriately managing children and adolescents with moderate-severe atopic dermatitis.
Appendix
Available only for authorised users
Literature
1.
Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol. 2020. https://​doi.​org/​10.​1111/​bjd.​19673. Epub ahead of print.
2.
Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186:23–31.
3.
Hanifin JM, Thurston M, Omoto M, EASI Evaluator Group, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11–8.PubMedCrossRef
4.
Conic RZ, Tamashunas NL, Damiani G, Fabbrocini G, Cantelli M, Young Dermatologists Italian Network, & Bergfeld, W. F. (2020). Comorbidities in pediatric alopecia areata. J Eur Acad Dermatol Venereol. 2020;34(12):2898–901.PubMedCrossRef
5.
Perugia C, Saraceno R, Ventura A, et al. Atopic dermatitis and dental manifestations. G Ital Dermatol Venereol. 2017;152:122–5.PubMed
6.
Damiani G, Gironi LC, Pacifico A, Pigatto P, Malagoli P, Bindi M, et al. Cutaneous and oral comorbidities in patients with geographic tongue: a multicenter multidisciplinary cross-sectional observational study. J Biol Regul Homeost Agents. 2021;35(21):339–44.PubMed
7.
Damiani G, Calzavara-Pinton P, Stingeni L, Hansel K, Cusano F, “Skin Allergy” Group of SIDeMaST, “ADOI” (Associazione Dermatologi Ospedalieri Italiani), “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale), & Pigatto P. Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatologic Therap. 2019;32(6):e13121.
8.
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32:657–82.PubMedCrossRef
9.
Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46:1053–101.PubMedCrossRef
10.
Chiricozzi A, Comberiati P, D’Auria E, Zuccotti G, Peroni DG. Topical corticosteroids for pediatric atopic dermatitis: Thoughtful tips for practice. Pharmacol Res. 2020;158:104878.PubMedCrossRef
11.
12.
Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol. 2005;53:S17-25.PubMedCrossRef
13.
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135:597–606.PubMedCrossRef
14.
Chiricozzi A, Belloni Fortina A, Galli E, Girolomoni G, Neri I, Ricci G, et al. Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel. Allergol Immunopathol (Madr). 2019;47:194–206.CrossRef
15.
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32:850–78.PubMedCrossRef
16.
Hoeger PH, Kinsler V, Yan AC, Harper J, Oranje AP, Bodemer CB, Larralde M, Luk D, Mendiratta V, Purvis D. Harper's Textbook of Pediatric Dermatology, 2 Volume Set, 4th Edition. 2019.
17.
Danby SG, Draelos ZD, Gold LFS, Danby SG, Draelos ZD, Gold LFS, et al. Vehicles for atopic dermatitis therapies: more than just a placebo. J Dermatolog Treat. 2020;16:1–14.
18.
Long CC, Finlay AY. The finger-tip unit–a new practical measure. Clin Exp Dermatol. 1991;16:444–7.PubMedCrossRef
19.
Hong E, Smith S, Fischer G. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatr Dermatol. 2011;28:393–6.PubMedCrossRef
20.
Thomas KS, Armstrong S, Avery A, Po AL, O’Neill C, Young S, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ. 2002;324:768.PubMedPubMedCentralCrossRef
21.
Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol. 2002;3:47–58.PubMedCrossRef
22.
Wood Heickman LK, Davallow Ghajar L, Conaway M, Rogol AD. Evaluation of hypothalamic-pituitary-adrenal axis suppression following cutaneous use of topical corticosteroids in children: a meta-analysis. Horm Res Paediatr. 2018;89:389–96.PubMedCrossRef
23.
Friedlander SF, Hebert AA, Allen DB, Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46:387–93.PubMedCrossRef
24.
Blume-Peytavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25:508–15.PubMedCrossRef
25.
Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ. 2003;21:326–67.
26.
van Velsen SG, Knol MJ, van Eijk RL, de Vroede MA, de Wit TC, Lam MG, et al. Bone mineral density in children with moderate to severe atopic dermatitis. J Am Acad Dermatol. 2010;63:824–31.PubMedCrossRef
27.
Zhao M, Liang Y, Shen C, Wang Y, Ma L, Ma X. Patient education programs in pediatric atopic dermatitis: a systematic review of randomized controlled trials and meta-analysis. Dermatol Ther (Heidelb). 2020;10:449–64.CrossRef
28.
Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol. 2017;153:1036–42.PubMedCrossRef
29.
Moret L, Anthoine E, Aubert-Wastiaux H, Le Rhun A, Leux C, Mazereeuw-Hautier J, et al. TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One. 2013;16(8):e76493.CrossRef
30.
31.
32.
Chehade A, Rao J, Topical Calcineurin Inhibitors. Topical Calcineurin Inhibitors Comprehensive Dermatologic Drug Therapy. 4th ed. 2021. p. 549–56.CrossRef
33.
Nakahara T, Morimoto H, Murakami N, Furue M. Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis. Pediatr Allergy Immunol. 2018;29:233–8.PubMedCrossRef
34.
Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol. 2010;163:70–7.PubMedCrossRef
35.
Mandelin JM, Remitz A, Virtanen HM, Malmberg LP, Haahtela T, Reitamo S. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. J Dermatolog Treat. 2010;21:167–70.PubMedCrossRef
36.
37.
Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharmaceutics. 2004;269:29–35.CrossRef
38.
Chittock J, Brown K, Cork MJ. Comparing the effect of a twice-weekly tacrolimus and betamethasone valerate dose on the subclinical epidermal barrier defect in atopic dermatitis. Acta Derm Venereol. 2015;95:653–8.PubMedCrossRef
39.
Dähnhardt D, Bastian M, Dähnhardt-Pfeiffer S, Buchner M, Fölster-Holst R. Comparing the effects of proactive treatment with tacrolimus ointment and mometasone furoate on the epidermal barrier structure and ceramide levels of patients with atopic dermatitis. J Dermatolog Treat. 2020;3:1–9.
40.
Remitz A, De Pità O, Mota A, Serra-Baldrich E, Vakirlis E, Kapp A. Position statement: topical calcineurin inhibitors in atopic dermatitis. Eur Acad Dermatol. 2018;32:2074–82.CrossRef
41.
Chen SL, Yan J, Wang FX. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatol Treat. 2010;21:144–56.CrossRef
42.
El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2009;54:76–87.PubMedCrossRef
43.
Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits. J Dermatol. 2018;45:936–42.PubMedPubMedCentralCrossRef
44.
Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.PubMedPubMedCentralCrossRef
45.
Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34:2717–44.PubMedCrossRef
46.
Luger T, Augustin M, Lambert J, Paul C, Pincelli C, Torrelo A. Unmet medical needs in the treatment of atopic dermatitis in infants: an expert consensus on safety and efficacy of pimecrolimus. Pediatr Allergy Immunol. 2021;3:414–24.CrossRef
47.
Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer AB Jr. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol. 2012;92:455–61.PubMedCrossRef
48.
Thaci D, Chambers C, Sidhu M, Dorsch B, Ehlken B, Fuchs S. Twice weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol. 2010;24:1040–6.PubMed
49.
Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020;69:356–69.PubMedCrossRef
50.
Wongpiyabovorn J, Soonthornchai W, Wilantho A, Palasuk M, Payungporn S, Sodsai P, et al. Effect of tacrolimus on skin microbiome in atopic dermatitis. Allergy. 2019;74:1400–6.PubMedCrossRef
51.
Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W, Ocular Co-Morbidities of Atopic Dermatitis. Part II: ocular disease secondary to treatments. Am J Clin Dermatol. 2019;20:807–15.PubMedCrossRef
52.
Ollech A, Yousif R, Kruse L, Wagner A, Kenner-Bell B, Chamlin S, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis. J Am Acad Dermatol. 2020;82:1409–14.PubMedCrossRef
53.
Radovic TC, Kostovic K, Ceovic R, Mokos ZB. Topical calcineurin inhibitors and malignancy risk. Int J Cancer Manag. 2017;10:e6173.CrossRef
54.
Castellsague J, Kuiper JG, Pottegård A, Anveden Berglind I, Dedman D, Gutierrez L, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. 2018;13(10):299–310.CrossRef
55.
Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151:594–9.PubMedPubMedCentralCrossRef
56.
Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83:375–81.PubMedCrossRef
57.
Rafiq M, Hayward A, Warren-Gash C, Denaxas S, Gonzalez-Izquierdo A, Lyratzopoulos G, et al. Allergic disease, corticosteroid use, and risk of hodgkin lymphoma: a United Kingdom nationwide case-control study. J Allergy Clin Immunol. 2020;145:868–76.PubMedPubMedCentralCrossRef
58.
Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP Jr. Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol. 2020;156:1066–73.PubMedCrossRef
59.
Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126:3–12.PubMedCrossRef
60.
Allen HB, Vaze ND, Choi C, Hailu T, Tulbert BH, Cusack CA, et al. The presence and impact of biofilm- producing staphylococci in atopic dermatitis. JAMA Dermatol. 2014;150:260–5.PubMedCrossRef
61.
62.
Kong HH, Segre JA. Skin microbiome: looking back to move forward. J Invest Dermatol. 2012;132:933–9.PubMedCrossRef
63.
Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22:850–9.PubMedPubMedCentralCrossRef
64.
65.
Petry V, Bessa GR, Poziomczyck CS, Oliveira CF, Weber MB, Bonamigo RR, et al. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012;87:729–34.PubMedCrossRef
66.
Kim J, Kim BE, Ahn K, Leung DYM. Interactions between atopic dermatitis and staphylococcus aureus infection: clinical implications. Allergy Asthma Immunol Res. 2019;11:593–60.PubMedPubMedCentralCrossRef
67.
Stephanie M. Bacterial colonization, overgrowth, and superinfection in atopic dermatitis. Clin Dermatol. 2018;36:641–7.CrossRef
68.
Rosen T, Albareda N, Rosenberg N, Alonso FG, Roth S, Zsolt I, et al. Efficacy and safety of ozenoxacin cream for treatment of adult and pediatric patients with impetigo a randomized clinical trial. Jama Dermatol. 2018;154:806–13.PubMedPubMedCentralCrossRef
69.
Bonamonte D, Belloni Fortina A, Neri L, et al. Fusidic acid in skin infections and infected atopic eczema. G Ital Dermatol Venereol. 2014;149:453–9.PubMed
70.
Bonamonte D, Belloni Fortina A, Neri L, Patrizi A. Topical antibiotics in the dermatological clinical practice: Indications, efficacy, and adverse effects. Dermatol Ther. 2020;12:e13824.
71.
Rangel SM, Paller AS. Bacterial colonization, overgrowth, and superinfection in atopic dermatitis. Clin Dermatol. 2018;36:641–7.PubMedCrossRef
72.
Chiu LS, Chow VC, Ling JM, Hon KL. Staphylococcus aureus carriage in the anterior nares of close contacts of patients with atopic dermatitis. Arch Dermatol. 2010;146:748–52.PubMedCrossRef
73.
74.
George SM, Karanovic S, Harrison DA, Rani A, Birnie AJ, Bath-Hextall FJ, et al. Interventions to reduce staphylococcus aureus in the management of eczema. Cochrane Database Syst Rev. 2019;10:CD003871.
75.
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59:e10-52.PubMedCrossRef
76.
Montravers P, Snauwaert A, Welsch C. Current guidelines and recommendations for the management of skin and soft tissue infections. Curr Opin Infect Dis. 2016;29:131–8.PubMedCrossRef
77.
Koch L, Cerpes U, Binder B, Cerroni L. Disseminated bullous impetigo in atopic dermatitis ('eczema staphylococcatum’). Eur Acad Dermatol Venereol. 2021;35:e280–2.CrossRef
78.
Galli L, Venturini E, Bassi A, Gattinara GC, Chiappini E, Defilippi C, Italian Pediatric Infectious Diseases Society; Italian Pediatric Dermatology Society, et al. Common community-acquired bacterial skin and soft-tissue infections in children: an intersociety consensus on impetigo, abscess, and cellulitis treatment. Clin Ther. 2019;41:532-551.e17.PubMedCrossRef
79.
Harkins CP, Holden MTG, Irvine AD. Antimicrobial resistance in atopic dermatitis: need for an urgent rethink. Ann Allergy Asthma Immunol. 2019;122:236–40.PubMedCrossRef
80.
Majewski S, Bhattacharya T, Asztalos M, Bohaty B, Durham KC, West DP, et al. Sodium hypochlorite body wash in the management of Staphylococcus aureus–colonized moderate-to-Severe atopic dermatitis in infants, children, and adolescents. Pediatric Dermatol. 2019;36:442–7.CrossRef
81.
Leung TH, Zhang LF, Wang J, Ning S, Knox SJ, Kim SK. Topical hypochlorite ameliorates NF-kappaB-mediated skin diseases in mice. J Clin Invest. 2013;123:5361–70.PubMedPubMedCentralCrossRef
82.
83.
Eriksson S. Antibacterial and antibiofilm effects of sodium hypochlorite against staphylococcus aureus isolates derived from patients with atopic dermatitis. Br J Dermatol. 2017;177:513–21.PubMedCrossRef
84.
Rerinck HC, Kamann S, Wollenberg A. Eczema herpeticatum: pathogenese und therapie [Eczema herpeticum: Pathogenesis and therapy]. Hautarzt. 2006;57:586–91.PubMedCrossRef
85.
Seegräber M, Worm M, Werfel T, Svensson A, Novak N, Simon D, et al. Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2020;34:1074–9.PubMedCrossRef
86.
87.
Ong PY, Leung DYM. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51:329–37.PubMedCrossRef
88.
Guzman AK, Schairer DO, Garelik JL, Cohen SR. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscumcontagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial. Int J Dermatol. 2018;57:1001–6.PubMedCrossRef
89.
Berger EM, Orlow SJ, Patel RR, Schaffer JV. Experience with molluscum contagiosum and associated inflammatory reactions in a pediatric dermatology practice: the bump that rashes. Arch Dermatol. 2012;148:1257–64.PubMedCrossRef
90.
Mathes EF, Oza V, Frieden IJ, Cordoro KM, Yagi S, Howard R, et al. “Eczema coxsackium” and unusualcutaneousfindings in an enterovirusoutbreak. Pediatrics. 2013;132:e149-57.PubMedPubMedCentralCrossRef
91.
Neri I, Dondi A, Wollenberg A, Ricci L, Ricci G, Piccirilli G, et al. Atypical forms of hand, foot, and mouth disease: a prospective study of 47 Italian children. Pediatr Dermatol. 2016;33:429–37.PubMedCrossRef
92.
Johnson VK, Hayman JL, McCarthy CA, Cardona ID. Successful treatment of eczema coxsackium with wet wrap therapy and low-dose topical corticosteroid. J Allergy Clin Immunol Pract. 2014;2:803–4.PubMedCrossRef
93.
Ikezawa Z, Kondo M, Okajima M, Nishimura Y, Kono M. Clinical usefulness of oral itraconazole, an antimycotic drug, for refractory atopic dermatitis. Eur J Dermatol. 2004;14:400–6.PubMed
94.
Darabi K, Hostetler SG, Bechtel MA, Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60:125–36.PubMedCrossRef
95.
Saunte DML, Gaitanis G, Hay RJ. Malassezia-associated skin diseases, the use of diagnostics and treatment. Front Cell Infect Microbiol. 2020;20(10):112.CrossRef
96.
Guglielmo A, Sechi A, Patrizi A, Gurioli C, Neri I. Head and neck dermatitis, a subtype of atopic dermatitis induced by Malassezia spp: clinical aspects and treatment outcomes in adolescent and adult patients. Pediatr Dermatol. 2021;38(1):109–14.PubMedCrossRef
97.
Mayser P, Kupfer J, Nemetz D, Schäfer U, Nilles M, Hort W, et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream - results of a double-blind, placebo- controlled study. Skin Pharmacol Physiol. 2006;19:153–8.PubMedCrossRef
98.
Morita E, Hide M, Yoneya Y, Kannbe M, Tanaka A, Yamamoto S. An assessment of the role of Candida albicans antigen in atopic dermatitis. J Dermatol. 1999;26:282–7.PubMedCrossRef
99.
Javad G, Taheri Sarvtin M, Hedayati MT, Hajheydari Z, Yazdani J, et al. Evaluation of Candida colonization and specific humoral responses against Candida albicans in patients with atopic dermatitis. Biomed Res Int. 2015;2015:142453.CrossRef
100.
Thammahong A, Kiatsurayanon C, Edwards SW, Rerknimitr P, Chiewchengchol D. The clinical significance of fungi in atopic dermatitis. Int J Dermatol. 2020;59:926–35.PubMedCrossRef
101.
Soeberdt M, Kilic A, Abels C. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Eur J Pharmacol. 2020;881:171242.CrossRef
102.
Fahrbach K, Tarpey J, Washington EB, Hughes R, Thom H, Neary MP, et al. Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: systematic literature review and network meta-analysis JC. Dermatol Ther (Heidelb). 2020;10:681–94.CrossRef
103.
Paller AS, Tom WL, Lebwohl MG, Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494–503.PubMedCrossRef
104.
Solimani F, Meier K, Ghoreschi K. Emergin topical and sistemi jak inhibitors in dermatology. Front Immunol. 2019;3(10):2847.CrossRef
105.
Rodrigues MA, Torres T. Jak/STA inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020;31:33–40.PubMedCrossRef
106.
Guttman-Yassky E, Hanifin JM, Boguniewicz M, Wollenberg A, Bissonnette R, Purohit V, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019;28:3–10.PubMed
107.
108.
Brar KK, Nicol NH, Boguniewicz M. Strategies for successful management of severe atopic dermatitis. J Allergy Clin Immunol Pract. 2019;7:1–16.PubMedCrossRef
109.
Janmohamed SR, Eichenfield LF, Ring J, Gutermuth J. Medical algorithm: diagnosis of atopic dermatitis in early childhood (part II). Allergy. 2020;00:1–4.
110.
Cadmus SD, Sebastian KR, Warren D, Hovinga CA, Croce EA, Reveles LA, et al. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: a randomized split-body control study. Pediatr Dermatol. 2019;36:437–41.PubMed
111.
Mirza SA. Serum triamcinolone levels during intensive, inpatient wet-dressing therapy. Clin Exp Dermatol. 2020;45:549–54.PubMedCrossRef
112.
Witte M, Krause L, Zillikens D, Shimanovich I. Black tea dressings - a rapidly effective treatment for facial dermatitis. J Dermatolog Treat. 2019;30:785–9.PubMedCrossRef
113.
Huiling H, Koh MJ, Lee HY, Ang SB. Pilot study of a customized nanotextile wet garment treatment on moderate and severe atopic dermatitis: a randomized clinical trial. Pediatr Dermatol. 2020;37:52–7.CrossRef
114.
Naylor GRS. Fabric-evoked prickle in worsted spun single jersey fabrics part 4: extension from wool to OptimTMfine Fiber. Text Res J. 2009;80:537–47.CrossRef
115.
Gauger A, Mempel M, Schekatz A, Schäfer T, Ring J, Abeck D. Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema. Dermatology. 2003;207:15–21.PubMedCrossRef
116.
Gauger A, Fischer S, Mempel M, Schaefer T, Foelster-Holst R, Abeck D, et al. Efficacy and functionality of silver-coated textiles in patients with atopic eczema. J Eur Acad Dermatol Venereol. 2006;20:534–41.PubMedCrossRef
117.
Zhai H, Dika E, Goldovsky M, Maibach HI. Tape-stripping method in man: comparison of evaporimetric methods. Skin Res Technol. 2007;13(2):207–10.PubMedCrossRef
118.
Hipler UC, Elsner P, Fluhr JW. A new silver-loaded cellulosic fiber with antifungal and antibacterial properties. Curr Probl Dermatol. 2006;33:165–78.PubMedCrossRef
119.
Park KY, Jang WS, Yang GW, Rho YH, Kim BJ, Mun SK, et al. A pilot study of silver-loaded cellulose fabric with incorporated seaweed for the treatment of atopic dermatitis. Clin Exp Dermatol. 2012;37:512–5.PubMedCrossRef
120.
Araújo CP, Gomes J, Vieira AP, Ventura F, Fernandes JC, Brito C. A proposal for the use of new silver-seaweed-cotton fibers in the treatment of atopic dermatitis. Cutan Ocul Toxicol. 2013;32:268–74.PubMedCrossRef
121.
Pluut OA, Bianco C, Jakasa I, Visser MJ, Krystek P, Larese-Filon F, et al. Percutaneous penetration of silver from a silver containing garment in healthy volunteers and patients with atopic dermatitis. Toxicol Lett. 2015;235:116–22.PubMedCrossRef
122.
Lopes C, Soares J, Tavaria F, Duarte A, Correia O, Sokhatska O, et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLoS One. 2015;10:e0142844.PubMedPubMedCentralCrossRef
123.
Ricci G, Patrizi A, Bendandi B, Menna G, Varotti E, Masi M. Clinical effectiveness of a silk fabric in the treatment of atopic dermatitis. Br J Dermatol. 2004;150:127–31.PubMedCrossRef
124.
Ricci G, Patrizi A, Mandrioli P, Specchia F, Medri M, Menna G, et al. Evaluation of the antibacterial activity of a specialsilk textile in the treatment of atopic dermatitis. Dermatology. 2006;213:224–7.PubMedCrossRef
125.
Koller DY, Halmerbauer G, Bock A, Engstler G. Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3-month trial. Pediatr Allergy Immunol. 2007;18:335–8.PubMedCrossRef
126.
Stinco G, Piccirillo F, Valent F. A randomized double-blind study to investigate the clinical efficacy of adding a non-migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology. 2008;217:191–5.PubMedCrossRef
127.
Fontanini C, Berti I, Monasta L, Longo G. DermaSilk in long-term control of infantile atopic dermatitis: a double blind randomized controlled trial. G Ital Dermatol Venereol. 2013;148:293–7.PubMed
128.
Thomas KS, Bradshaw LE, Sach TH, Cowdell F, Batchelor JM, Lawton S, et al. Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: theCLOTHES trial. Health Technol Assess. 2017;21:1–260.PubMedPubMedCentral
129.
Srour J, Wollenberg A. Evaluation of antimicrobial textiles for atopic dermatitis. Br J Dermatol. 2018;179:e19.
130.
Jaros J, Wilson C, Shi VY. Fabric selection in atopic dermatitis: an evidence based review. Am J Clin Dermatol. 2020;21:467–82.PubMedCrossRef
131.
Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: international Eczema council consensus statement. Br J Dermatol. 2018;178:768–75.PubMedPubMedCentralCrossRef
132.
Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78:733-740.e11.PubMedCrossRef
133.
Misery L, Belloni Fortina A, El Hachem M, Chernyshov P, von Kobyletzki L, Heratizadeh A, et al. A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force. J Eur Acad Dermatol Venereol. 2021;35:787–96.PubMedCrossRef
134.
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, American Academy of Dermatology, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327–49.PubMedPubMedCentralCrossRef
135.
Chan TC, Wu NL, Wong LS. Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update. J Formos Med Assoc. 2020;18:18:S0929-664630237–0.
136.
Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63:925–46.PubMedCrossRef
137.
Amber T, Tabassum S. Cyclosporin in dermatology: a practical compendium. Dermatol Ther. 2020;30:e13934.
138.
Caproni M, Salvatore E, Cardinali C, Brazzini B, Fabbri P. Soluble CD30 andcyclosporin in severe atopic dermatitis. Int Arch Allergy Immunol. 2000;121:324–8.PubMedCrossRef
139.
Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133:429–38.PubMedCrossRef
140.
Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21:606–19.PubMed
141.
Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol. 1996;34:1016–21.PubMedCrossRef
142.
Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporine. Br J Dermatol. 1996;135(Suppl 48):21–4.PubMedCrossRef
143.
Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142:52–8.PubMedCrossRef
144.
El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013;172:351–6.PubMedCrossRef
145.
Irvine AD, Jones AP, Beattie P, Baron S, Browne F, Ashoor F, et al. A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT). Br J Dermatol. 2018;179:1297–306.PubMedCrossRef
146.
Damiani G, Calzavara-Pinton P, Stingeni L, Hansel K, Cusano F, “Skin Allergy” Group of SIDeMaST; “ADOI” (Associazione Dermatologi Ospedalieri Italiani); “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale), Pigatto PDM. Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther. 2019;32:e13121.PubMedCrossRef
147.
Lansang P, Lara-Corrales I, Bergman JN, Hong CH, Joseph M, Kim VHD, et al. Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section IV: consensus statements on the assessment and management of pediatric atopic dermatitis. J Cutan Med Surg. 2019;23:32s–9s.PubMedCrossRef
148.
Hernández-Martín A, Noguera-Morel L, Bernardino-Cuesta B, Torrelo A, Pérez-Martin MA, Aparicio-López C, et al. Cyclosporine A for severe atopic dermatitis in children efficacy and safety in a retrospective study of 63 patients. J Eur Acad Dermatol Venereol. 2017;31:837–42.PubMedCrossRef
149.
Proudfoot LE, Powell AM, Ayis S, Barbarot S, Baselga Torres E, Deleuran M, et al. The European treatment of severe atopic eczema in children taskforce (TREAT) survey. J Eur Acad Dermatol Venereol. 2013;32:850–78.
150.
Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochwerg B, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156:1–10.PubMedCentralCrossRef
151.
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16:145–54.PubMedCrossRef
152.
Weathrhead SC, Wahie S, Reynolds NY. An open label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156:346–51.CrossRef
153.
Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128:353–9.PubMedCrossRef
154.
Dvorakova V, O’Regan GM, Irvine AD. Methotrexate for severe childhood atopic dermatitis: clinical experience in a tertiary center. Pediatr Dermatol. 2017;34:528–34.PubMedCrossRef
155.
Anderson K, Putterman E, Rogers RS, Patel D, Treat JR, Castelo-Soccio L. Treatment of severe pediatric atopic dermatitis with methotrexate: a retrospective review. Pediatr Dermatol. 2019;36:298–302.PubMedCrossRef
156.
157.
Murphy LA, Atherton DJ. Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency. Pediatr Dermatol. 2003;20:531–4.PubMedCrossRef
158.
Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68:29–35.PubMedCrossRef
159.
Chong JH, Koh MJA. Non-topical management of recalcitrant paediatric atopic dermatitis. Arch Dis Child. 2017;102:681–6.PubMedCrossRef
160.
Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28:689–94.PubMedCrossRef
161.
Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolatemofetil for severe childhood atopic dermatitis: experience in14 patients. Br J Dermatol. 2007;157:127–32.PubMedCrossRef
162.
Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143:385–91.PubMedCrossRef
163.
164.
Silverberg NB, Durán-McKinster C. Special considerations for therapy of pediatric atopic dermatitis. Dermatol Clin. 2017;35:351–63.PubMedCrossRef
165.
Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. Immunol Allergy Clin North Am. 2015;35:161–83.PubMedCrossRef
166.
He A, Feldman SR, Fleischer AB Jr. An assessment of the use of antihistamines in the management of atopic dermatitis. J Am Acad Dermatol. 2018;79:92–6.PubMedCrossRef
167.
Nowicki RJ, Trzeciak M, Kaczmarski M, Wilkowska A, Czarnecka-Operacz M, Kowalewski C, Atopic dermatitis, et al. Interdisciplinary diagnostic and therapeutic recommendations of the polish dermatological society, polish society of allergology, polish pediatric society and polish society of family medicine. Part II. Systemic treatment and new therapeutic methods. Postepy Dermatol Alergol. 2020;37:129–34.PubMedPubMedCentralCrossRef
168.
Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30:729–47.PubMedCrossRef
169.
van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, Jupiter A, Matterne U, Weisshaar E. No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane Systematic review. System Rev. 2014;3:25.CrossRef
170.
171.
Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019;1:CD012167.PubMed
172.
Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 2000;105(6 Pt 2):S622-7.PubMedCrossRef
173.
Yu SH, Attarian H, Zee P, Silverberg JI. Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis. 2016;27:50–8.PubMedCrossRef
174.
Schad CA, Skoner DP. Antihistamines in the pediatric population: achieving optimal outcomes when treating seasonal allergic rhinitis and chronic urticaria. Allergy Asthma Proc. 2008;29:7–13.PubMedCrossRef
175.
Food and Drug Administration HaHS. Labeling of diphenhydramine-containing drug products for over-the-counter human use. Final rule Fed Regist. 2002;2:72555–9.
176.
Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, Guidelines of care for the management of atopic dermatitis: section 2, et al. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116–32.PubMedPubMedCentralCrossRef
177.
Watanabe S, Narisawa Y, Arase S, Okamatsu H, Ikenaga T, Tajiri Y, et al. Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol. 2003;111:587–91.PubMedCrossRef
178.
Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007;56:661–7.PubMedCrossRef
179.
180.
181.
Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A. 2010;107:2159–64.PubMedPubMedCentralCrossRef
182.
183.
Makrgeorgou A, Leonardi‐Bee J, Bath‐Hextall FJ, Murrell DF, Tang MLK, Roberts A et al. Cochrane Skin Group. Cochrane Database Syst Rev. 2018;11(11):CD006135.
184.
Kim JY, Park BK, Park HJ, Park YH, Kim BO, Pyo S. Atopic dermatitis-mitigating effects of new Lactobacillus strain, Lactobacillus sakei probio 65 isolated from Kimchi. J Appl Microbiol. 2013;115:517–26.PubMedCrossRef
185.
Park SB, Im M, Lee Y, Lee JH, Lim J, Park YH, Seo YJ. Effect of emollients containing vegetable-derived lactobacillusin the treatment of atopic dermatitis symptoms: split-body clinical trial. Ann Dermatol. 2014;26:150–5.PubMedPubMedCentralCrossRef
186.
Baldwin H, Aguh C, Andriessen A, Benjamin L, Ferberg AS, Hooper D, et al. Atopic dermatitis and the role of skin micobiome in choosing prevention, treatment and maintenance options. J Drugs Dermatol. 2020;19(10):935–40.PubMedCrossRef
187.
Seitè S, Zelenkova H, Martin R. Clinical efficacy of emollient in atopic dermatitis patients-relationship with the skin microbiota modification. Clin Cosmet Invest Dermatol. 2017;10:25–35.CrossRef
188.
Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R, et al. Effect of nonpathogenic gram negative bacterium vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol. 2008;159:1357–63.PubMedCrossRef
189.
Butler É, Lundqvist C, Axelsson J. Lactobacillus reuteri DSM 17938 as a novel topical cosmetic ingredient: a proof of concept clinical study in adults with atopic dermatitis. Microorganisms. 2020;8:1026.PubMedCentralCrossRef
190.
Holme SA, Anstey AV. Phototherapy and PUVA photochemotherapy in children. Photodermatol Photoimmunol Photomed. 2004;20:69–75.PubMedCrossRef
191.
Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed. 2007;23:106–12.PubMedCrossRef
192.
Ortiz-Salvador JM, Pérez-Ferriols A. Phototherapy in Atopic Dermatitis. Adv Exp Med Biol. 2017;996:279–86.PubMedCrossRef
193.
Rodenbeck DL, Silverberg JI, Silverberg NB. Phototherapy for atopic dermatitis. Clin Dermatol. 2016;34:607–13.PubMedCrossRef
194.
Darrigade AS. Traitements topiques et photothérapie dans la dermatite atopique: topical treatments and phototherapy in atopic dermatitis. Ann Dermatol Venereol. 2019;146:128S5-129S5.CrossRef
195.
Farahnik B, Patel V, Beroukhim K, Zhu TH, Abrouk M, Nakamura M, et al. Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability. Psoriasis (Auckl). 2016;6:105–11.
196.
Cameron H, Yule S, Dawe RS, Ibbotson SH, Moseley H, Ferguson J. Review of an established UK home phototherapy service 1998–2011: improving access to a cost-effective treatment for chronic skin disease. Public Health. 2014;128:317–24.PubMedCrossRef
197.
Koek MB, Buskens E, Steegmans PH, van Weelden H, Bruijnzeel-Koomen CA, Sigurdsson V. UVB phototherapy in an outpatient setting or at home: a pragmatic randomised single-blind trial designed to settle the discussion. The PLUTO study. BMC Med Res Methodol. 2006;1(6):39.CrossRef
198.
Nakajima S, Nomura T, Common J, Kabashima K. Insights into atopic dermatitis gained from genetically defined mouse models. J Allergy Clin Immunol. 2019;143:13–25.PubMedCrossRef
199.
200.
201.
Thomson J, Wernham AGH, Williams HC. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. Br J Dermatol. 2018;178:897–902.PubMedCrossRef
202.
Thaçi D, Simpson E L, Deleuran M, Kataoka Y, Chen Z, Gadkari A, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94:266–75.PubMedCrossRef
203.
Simpson E, Paller AS, Siegfried EC. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitisa phase 3 randomized clinical trial. JAMA Dermatol. 2020;156:44–56.PubMedCrossRef
204.
Calzavara-Pinton P, Belloni Fortina A, Bonamonte D, Marseglia GL, Miraglia Del Giudice M, Musarra A, Diagnosis and management of moderate to severe atopic dermatitis in adolescents, et al. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP). Ital J Dermatol Venerol. 2021;156:184–97.PubMed
205.
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83:1282–93.PubMedCrossRef
206.
Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, et al. EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76:988–1009.PubMedCrossRef
207.
208.
Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145:173–82.PubMedCrossRef
209.
Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2020;17:S1081-1206.
210.
Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a Phase 2b randomized clinical trial. JAMA Dermatol. 2020;156:411–20.PubMedPubMedCentralCrossRef
211.
Simpson E, Blauvelt A, Guttman-Yassky E, et al. Efficacy and safety of tralokinumab monotherapy in adult patients with moderate-to-severe atopic dermatitis: results from two 52-week Phase 3 trials (ECZTRA 1 and ECZTRA 2). Presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX). 2020;4(6).
212.
Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized Phase 2a clinical trial. J Am Acad Dermatol. 2019;80:1013–21.PubMedCrossRef
213.
Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(482–493):e487.
214.
Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double blind, Phase 2a trial. J Am Acad Dermatol. 2018;78(872–881):e876.
215.
Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184:5298–307.PubMedCrossRef
216.
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242–55.PubMedCrossRef
217.
Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019;24(8):212595.
218.
Guttman-Yassky E, Thaci D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145:877–84.PubMedCrossRef
219.
Napolitano M, Fabbrocini G, Cinelli E, Stingeni L, Patruno C. Profile of baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: a short review on the emerging clinical evidence. J Asthma Allergy. 2020;13:89–94.PubMedPubMedCentralCrossRef
220.
Napolitano M, Ruggiero A, Fontanella G, Fabbrocini G, Patruno C. New emergent therapies for atopic dermatitis: a review of safety profile with respect to female fertility, pregnancy, and breastfeeding. Dermatol Ther. 2020;30:e14475.
221.
222.
Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis. A phase 2 randomized clinical trial. JAMA Dermatol. 2019;155:1371–9.PubMedPubMedCentralCrossRef
223.
Rizk P, Rodenas M, De Benedetto A. Allergen immunotherapy and atopic dermatitis: the good, the bad, and the unknown. Curr Allergy Asthma Rep. 2019;19:57.PubMedCrossRef
224.
Pajno GB, Bernardini R, Peroni D, Arasi S, Martelli A, Landi M, et al. Clinical practice recommendations for allergen specific immnotherapy in children. The Italian Consensus report. Ital J Pediatrics. 2017;23(43):13.CrossRef
225.
Muraro A, Roberts G, Halken S, Agache I, Angier E, Fernandez-Rivas M, et al. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy. 2018;73:739–43.PubMedCrossRef
226.
Ridolo E, Martignago I, Riario-Sforza GG, Incorvaia C. Allergen immunotherapy in atopic dermatitis. Expert Rev Clin Immunol. 2018;4:61–8.CrossRef
227.
Tam HH, Calderon MA, Manikam L, Nankervis H, Núñez IG, Williams HC, et al. Specific allergen immunotherapy for the treatment of atopic eczema: a cochrane systematic review. Allergy. 2016;71:1345–56.PubMedCrossRef
228.
Liu L, Chen J, Xu J, Yang Q, Gu C, Ni C, et al. Sublingual immunotherapy of atopic dermatitis in mite –sensitized patients: a multi-centre, randomized, double blind, placebo controlled study. Artif Cells Nanomed Biotechnol. 2019;47:35540–3547.
229.
Galli E, Chini L, Nardi S, Benincori N, Panei P, Fraioli G, et al. Use of oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergolol Immnophatol (Madr). 1994;22:18–22.
230.
Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120:164–70.PubMedCrossRef
231.
Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the joint task force practice parameter and american academy of dermatology guidelines. J Allergy Clin Immunol. 2017;139:S49–57.PubMedCrossRef
232.
Chu H, Park KH, Kim SM, Lee JH, Park JW, Lee KH, et al. Allergen-specific immunotherapy for patients with atopic dermatitis sensitized to animal dander. Immun Inflamm Dis. 2020;8:165–9.PubMedPubMedCentralCrossRef
233.
Cacciapuoti S, Luciano MA, Megna M, Annunziata MC, Napolitano M, Patruno C, et al. The role of thermal water in chronic skin diseases management: a review of the literature. J Clin Med. 2020;9:3047.PubMedCentralCrossRef
234.
Harari M. Climatotherapy of skin diseases at the dead sea – an update. Anales de Hidrología Médica. 2012;5:39–51.
235.
Heinlin J, Schiffner-Rohe J, Schiffner R, Einsele-Krämer B, Landthaler M, Klein A, et al. A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs narrow-band UVB monotherapy for atopic dermatitis. J Eur Acad Dermatol Venereol. 2011;25:765–73.PubMedCrossRef
236.
Merial-Kieny C, Castex-Rizzi N, Selas B, Mery S, Guerrero D. Avène thermal spring water: an active component with specific properties. J Eur Acad Dermatol Venereol. 2011;25:2–5.PubMedCrossRef
237.
Pigatto P. The efficacy of avène thermal spring water in light to moderate atopicdermatitis. Ann Dermatol Venereol. 2005;132:6S16–8.PubMed
238.
Giannetti A. The hydrotherapy centre in avène-les-bains a controlled study in atopic dermatitis. Ann Dermatol Venereol. 2005;132:6S12–5.PubMed
239.
Taieb C, Myon E. Dermatite atopique: Impact de l’hydrothèrapie sur la qualite’ de vie. Ann Dermatol Venereol. 2005;132:6S19–21.PubMedCrossRef
240.
Dikova A. An observational study on patients suffering from atopic dermatitis undergoing balneotherapy. Proceeding in J Am Acad Dermatol. 2016;76:AB41.
241.
Farina S, Gisondi P, Zanoni M, Pace M, Rizzoli L, Baldo E, et al. Balneotherapy for atopic dermatitis in children at Comano spa in Trentino, Italy. J Dermatolog Treat. 2011;22:366–71.PubMedCrossRef
242.
Guerrero D, Garrigue E. Eau thermale d’Avène et dermatite atopique: avène’s thermal water and atopic dermatitis. Ann Dermatol Venereol. 2017;144:S27–34.PubMedCrossRef
243.
Martin H, Laborel-Préneron E, Fraysse F, Nguyen T, Schmitt AM, Redoulès D, et al. Aquaphilus dolomiae extract counteracts the effects of cutaneous S. aureus secretome isolated from atopic children on CD4 T cell activation. Pharm Biol. 2016;54:2782–5.PubMedCrossRef
244.
Aries MF, Hernandez-Pigeon H, Vaissière C, Delga H, Caruana A, Lévêque M, et al. Anti-inflammatory and immunomodulatory effects of Aquaphilus dolomiae extract on in vitro models. Clin Cosm Investig Dermatol. 2016;9:421–34.CrossRef
245.
Seité S. Thermal waters as cosmeceuticals: La Roche Posay thermal spring waterexample. Clin Cosmet Investing Dermatol. 2013;6:23–8.CrossRef
246.
Zeichner J, Seite S. From probiotic to prebiotic using thermal spring water. J Drugs Dermatol. 2018;17:657–62.PubMed
247.
Pedron R, Esposito A, Bianconi I, Pasolli E, Tett A, Asnicar F, et al. Genomic and metagenomic insights into the microbial community of a thermal spring. Microbiome. 2019;7:8.PubMedPubMedCentralCrossRef
248.
Galli E, Neri I, Ricci G, Baldo E, Barone M, Belloni Fortina A, et al. Consensus conference on clinical management on pediatric atopic dermatitis. Ital J Pediatr. 2016;2(42):26.CrossRef
249.
Piano nazionale della cronicità. A cura di Direzione generale della Programmazione sanitaria - Ministero della Salute. Anno. 2016.
250.
Olsson M, Bajpai R, Yew YW, Koh MJA, Thng S, Car J, et al. Association between health-related quality of life and health-related costs among children with atopic dermatitis and their caregivers: across-sectional study. Pediatr Dermatol. 2020;37:284–93.PubMedCrossRef
251.
Maksimovic N, Zaric M, Reljic V, Nikolic M, Gazibara T. Factors associated with improvement of quality of life among parents of children with atopic dermatitis:1-year prospective cohort study. Eur Acad Dermatol Venereol. 2020;34:325–32.CrossRef
252.
Bass AM, Anderson KL, Feldman SR. Interventions to increase treatment adherence in pediatric atopic dermatitis: a systematic review. J Clin Med. 2015;4:231–42.PubMedPubMedCentralCrossRef
253.
Peters EM, Michenko A, Kupfer J, Kummer W, Wiegand S, Niemeier V, et al. Mental stress in atopic dermatitis– neuronal plasticity and the cholinergic system are affected in atopic dermatitis and in response to acute experimental mental stress in a randomized controlled pilot study. PLoS One. 2014;9:e113552.PubMedPubMedCentralCrossRef
254.
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychosocial burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135:984–91.PubMedPubMedCentralCrossRef
255.
Ersser SJ, Cowdell F, Latter S, Gardiner E, Flohr C, Thompson AR, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2014;2014(7):CD004054.PubMedCentral
256.
Eicher L, Knop M, Aszodi N, Senner S, French LE, Wollenberg A. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019;33:2253–63.PubMedCrossRef
257.
El Hachem M, Di Mauro G, Rotunno R, Giancristoforo S, De Ranieri C, Carlevaris CM, et al. Pruritus in pediatric patients with atopic dermatitis: a multidisciplinary approach - summary document from an Italian expert group. Ital J Pediatr. 2020;46:11.PubMedPubMedCentralCrossRef
258.
Leibovic V, Magora F, Cohen S, Ingber A. Effects of virtual reality immersion and audiovisual distraction techniques for patients with pruritus. Pain Res Manag. 2009;14:283–6.CrossRef
Metadata
Title
Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP)
Authors
Elena Galli
Anna Belloni Fortina
Giampaolo Ricci
Nunzia Maiello
Iria Neri
Ermanno Baldo
Irene Berti
Domenico Bonamonte
Lucetta Capra
Elena Carboni
Rossella Carello
Francesca Caroppo
Giovanni Cavagni
Iolanda Chinellato
Francesca Cipriani
Pasquale Comberiati
Andrea Diociaiuti
Vito Di Lernia
Marzia Duse
Cesare Filippeschi
Arianna Giannetti
Mattia Giovannini
Amelia Licari
Gian Luigi Marseglia
Manuela Pace
Annalisa Patrizi
Giovanni Battista Pajno
Diego Peroni
Alberto Villani
Lawrence Eichenfield
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2022
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-022-01278-7

Other articles of this Issue 1/2022

Italian Journal of Pediatrics 1/2022 Go to the issue

Research

First Italian experience using the automated craniofacial gestalt analysis on a cohort of pediatric patients with multiple anomaly syndromes

Review

Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Commentary

Genetics and”democracy”

Case report

Interstitial deletions of chromosome 1p: novel 1p31.3p22.2 microdeletion in a newborn with craniosynostosis, coloboma and cleft palate, and review of the genomic and phenotypic profiles

Research

Children at risk of domestic accidents when are locked up at home: the other side of COVID-19 outbreak lockdown

Research

Incidental occurrence of neutropenia in children hospitalised for COVID-19